{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:47:29Z","timestamp":1789069649814,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00467-018-4034-z","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T13:43:57Z","timestamp":1537451037000},"page":"2289-2298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-4096","authenticated-orcid":false,"given":"Johannes","family":"Holle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Berenberg-Go\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ortraud","family":"Beringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Thumfart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"4034_CR1","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/nejm199804233381707","volume":"338","author":"SR Orth","year":"1998","unstructured":"Orth SR, Ritz E (1998) The nephrotic syndrome. N Engl J Med 338:1202\u20131211. \n                    https:\/\/doi.org\/10.1056\/nejm199804233381707","journal-title":"N Engl J Med"},{"key":"4034_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrneph.2014.217","volume":"11","author":"HT Cook","year":"2015","unstructured":"Cook HT, Pickering MC (2015) Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 11:14\u201322. \n                    https:\/\/doi.org\/10.1038\/nrneph.2014.217","journal-title":"Nat Rev Nephrol"},{"key":"4034_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMra1108178","volume":"366","author":"S Sethi","year":"2012","unstructured":"Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis\u2014a new look at an old entity. N Engl J Med 366:1119\u20131131. \n                    https:\/\/doi.org\/10.1056\/NEJMra1108178","journal-title":"N Engl J Med"},{"key":"4034_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semnephrol.2011.06.005","volume":"31","author":"S Sethi","year":"2011","unstructured":"Sethi S, Fervenza FC (2011) Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 31:341\u2013348. \n                    https:\/\/doi.org\/10.1016\/j.semnephrol.2011.06.005","journal-title":"Semin Nephrol"},{"key":"4034_CR5","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1172\/jci43343","volume":"120","author":"R Martinez-Barricarte","year":"2010","unstructured":"Martinez-Barricarte R, Heurich M, Valdes-Canedo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, Rodriguez de Cordoba S (2010) Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120:3702\u20133712. \n                    https:\/\/doi.org\/10.1172\/jci43343","journal-title":"J Clin Invest"},{"key":"4034_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grunfeld JP, Niaudet P, Lesavre P, Fremeaux-Bacchi V (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82:454\u2013464. \n                    https:\/\/doi.org\/10.1038\/ki.2012.63","journal-title":"Kidney Int"},{"key":"4034_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","volume":"66","author":"M Noris","year":"2015","unstructured":"Noris M, Remuzzi G (2015) Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, Membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis 66:359\u2013375. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2015.03.040","journal-title":"Am J Kidney Dis"},{"key":"4034_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","volume":"71","author":"P Iatropoulos","year":"2016","unstructured":"Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G (2016) Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 71:131\u2013142. \n                    https:\/\/doi.org\/10.1016\/j.molimm.2016.01.010","journal-title":"Mol Immunol"},{"key":"4034_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1055\/s-0034-1376334","volume":"40","author":"X Xiao","year":"2014","unstructured":"Xiao X, Pickering MC, Smith RJ (2014) C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Semin Thromb Hemost 40:465\u2013471. \n                    https:\/\/doi.org\/10.1055\/s-0034-1376334","journal-title":"Semin Thromb Hemost"},{"key":"4034_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00467-011-2059-7","volume":"27","author":"DF Lu","year":"2012","unstructured":"Lu DF, Moon M, Lanning LD, McCarthy AM, Smith RJ (2012) Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol 27:773\u2013781. \n                    https:\/\/doi.org\/10.1007\/s00467-011-2059-7","journal-title":"Pediatr Nephrol"},{"key":"4034_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2215\/cjn.03480708","volume":"4","author":"SH Nasr","year":"2009","unstructured":"Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD (2009) Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 4:22\u201332. \n                    https:\/\/doi.org\/10.2215\/cjn.03480708","journal-title":"Clin J Am Soc Nephrol"},{"key":"4034_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1055\/s-0034-1375299","volume":"40","author":"M Vivarelli","year":"2014","unstructured":"Vivarelli M, Emma F (2014) Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost 40:472\u2013477. \n                    https:\/\/doi.org\/10.1055\/s-0034-1375299","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 1","key":"4034_CR13","first-page":"4","volume":"75","author":"RT Krmar","year":"2011","unstructured":"Krmar RT, Holtback U, Linne T, Berg UB, Celsi G, Soderberg MP, Wernerson A, Szakos A, Larsson S, Skattum L, Barany P (2011) Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange. Clin Nephrol 75(Suppl 1):4\u201310","journal-title":"Clin Nephrol"},{"key":"4034_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MNH.0b013e32835da24c","volume":"22","author":"CM Nester","year":"2013","unstructured":"Nester CM, Smith RJ (2013) Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens 22:231\u2013237. \n                    https:\/\/doi.org\/10.1097\/MNH.0b013e32835da24c","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4034_CR15","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00467-015-3111-9","volume":"30","author":"K Haffner","year":"2015","unstructured":"Haffner K, Michelfelder S, Pohl M (2015) Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression. Pediatr Nephrol 30:1951\u20131959. \n                    https:\/\/doi.org\/10.1007\/s00467-015-3111-9","journal-title":"Pediatr Nephrol"},{"key":"4034_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V, HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339. \n                    https:\/\/doi.org\/10.1007\/s00467-015-3076-8","journal-title":"Pediatr Nephrol"},{"key":"4034_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2215\/cjn.12901211","volume":"7","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7:748\u2013756. \n                    https:\/\/doi.org\/10.2215\/cjn.12901211","journal-title":"Clin J Am Soc Nephrol"},{"key":"4034_CR18","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMc1112273","volume":"366","author":"E Daina","year":"2012","unstructured":"Daina E, Noris M, Remuzzi G (2012) Eculizumab in a patient with dense-deposit disease. N Engl J Med 366:1161\u20131163. \n                    https:\/\/doi.org\/10.1056\/NEJMc1112273","journal-title":"N Engl J Med"},{"key":"4034_CR19","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1097\/hjh.0000000000001039","volume":"34","author":"E Lurbe","year":"2016","unstructured":"Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D, Rascher W, Redon J, Schaefer F, Seeman T, Sinha M, Stabouli S, Webb NJ, Wuhl E, Zanchetti A (2016) 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 34:1887\u20131920. \n                    https:\/\/doi.org\/10.1097\/hjh.0000000000001039","journal-title":"J Hypertens"},{"key":"4034_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/asn.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. \n                    https:\/\/doi.org\/10.1681\/asn.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"4034_CR21","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.ki.5002231","volume":"71","author":"A Akcan-Arikan","year":"2007","unstructured":"Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL (2007) Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 71:1028\u20131035. \n                    https:\/\/doi.org\/10.1038\/sj.ki.5002231","journal-title":"Kidney Int"},{"key":"4034_CR22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/nep.12382","volume":"20","author":"Y Okuda","year":"2015","unstructured":"Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y, Hataya H, Fukuzawa R, Ogata K, Honda M (2015) Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children. Nephrology (Carlton) 20:286\u2013292. \n                    https:\/\/doi.org\/10.1111\/nep.12382","journal-title":"Nephrology (Carlton)"},{"key":"4034_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1681\/asn.2015040385","volume":"27","author":"F Bu","year":"2016","unstructured":"Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, Azaiez H, Black-Ziegelbein EA, Meyer NC, Kolbe DL, Li Y, Frees K, Schnieders MJ, Thomas C, Nester C, Smith RJ (2016) High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 27:1245\u20131253. \n                    https:\/\/doi.org\/10.1681\/asn.2015040385","journal-title":"J Am Soc Nephrol"},{"key":"4034_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/jmg.40.9.676","volume":"40","author":"HP Neumann","year":"2003","unstructured":"Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Konigsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF (2003) Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 40:676\u2013681","journal-title":"J Med Genet"},{"key":"4034_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/jmg.2005.038315","volume":"43","author":"MA Abrera-Abeleda","year":"2006","unstructured":"Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, Jozsi M, Zipfel PF, Hageman GS, Smith RJ (2006) Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 43:582\u2013589. \n                    https:\/\/doi.org\/10.1136\/jmg.2005.038315","journal-title":"J Med Genet"},{"key":"4034_CR26","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1093\/hmg\/ddg363","volume":"12","author":"J Caprioli","year":"2003","unstructured":"Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M (2003) Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 12:3385\u20133395. \n                    https:\/\/doi.org\/10.1093\/hmg\/ddg363","journal-title":"Hum Mol Genet"},{"key":"4034_CR27","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1056\/NEJMc1107484","volume":"365","author":"Q Chen","year":"2011","unstructured":"Chen Q, Muller D, Rudolph B, Hartmann A, Kuwertz-Broking E, Wu K, Kirschfink M, Skerka C, Zipfel PF (2011) Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 365:2340\u20132342. \n                    https:\/\/doi.org\/10.1056\/NEJMc1107484","journal-title":"N Engl J Med"},{"key":"4034_CR28","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fremeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodriguez de Cordoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT (2013) C3 glomerulopathy: consensus report. Kidney Int 84:1079\u20131089. \n                    https:\/\/doi.org\/10.1038\/ki.2013.377","journal-title":"Kidney Int"},{"key":"4034_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00467-015-3310-4","volume":"32","author":"M Riedl","year":"2017","unstructured":"Riedl M, Thorner P, Licht C (2017) C3 glomerulopathy. Pediatr Nephrol 32:43\u201357. \n                    https:\/\/doi.org\/10.1007\/s00467-015-3310-4","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"4034_CR30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2215\/CJN.09080817","volume":"13","author":"Rupali S. Avasare","year":"2018","unstructured":"Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, Li Y, Gharavi AG, Appel GB (2018) Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol. \n                    https:\/\/doi.org\/10.2215\/cjn.09080817","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"4034_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40620-013-0008-1","volume":"27","author":"N Besbas","year":"2014","unstructured":"Besbas N, Gulhan B, Gucer S, Korkmaz E, Ozaltin F (2014) A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J Nephrol 27:457\u2013460. \n                    https:\/\/doi.org\/10.1007\/s40620-013-0008-1","journal-title":"J Nephrol"},{"key":"4034_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12882-017-0802-4","volume":"19","author":"T Welte","year":"2018","unstructured":"Welte T, Arnold F, Kappes J, Seidl M, Haffner K, Bergmann C, Walz G, Neumann-Haefelin E (2018) Treating C3 glomerulopathy with eculizumab. BMC Nephrol 19:7. \n                    https:\/\/doi.org\/10.1186\/s12882-017-0802-4","journal-title":"BMC Nephrol"},{"key":"4034_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.smim.2016.06.002","volume":"28","author":"CM Nester","year":"2016","unstructured":"Nester CM, Smith RJ (2016) Complement inhibition in C3 glomerulopathy. Semin Immunol 28:241\u2013249. \n                    https:\/\/doi.org\/10.1016\/j.smim.2016.06.002","journal-title":"Semin Immunol"},{"key":"4034_CR34","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s00467-013-2503-y","volume":"28","author":"S Gurkan","year":"2013","unstructured":"Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ (2013) Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 28:1975\u20131981. \n                    https:\/\/doi.org\/10.1007\/s00467-013-2503-y","journal-title":"Pediatr Nephrol"},{"key":"4034_CR35","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2215\/CJN.01360215","volume":"10","author":"MJ Oosterveld","year":"2015","unstructured":"Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, Groothoff JW (2015) Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol 10:1773\u20131782. \n                    https:\/\/doi.org\/10.2215\/CJN.01360215","journal-title":"Clin J Am Soc Nephrol"},{"key":"4034_CR36","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00467-017-3619-2","volume":"32","author":"C Lebreton","year":"2017","unstructured":"Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-Bacchi V, Sellier-Leclerc AL (2017) C3 glomerulopathy and eculizumab: a report on four paediatric cases. Pediatr Nephrol 32:1023\u20131028. \n                    https:\/\/doi.org\/10.1007\/s00467-017-3619-2","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"4034_CR37","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","volume":"93","author":"Andrew S. Bomback","year":"2018","unstructured":"Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB (2018) C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. \n                    https:\/\/doi.org\/10.1016\/j.kint.2017.10.022","journal-title":"Kidney International"},{"key":"4034_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/cjn.04700513","volume":"9","author":"NR Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT (2014) C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 9:46\u201353. \n                    https:\/\/doi.org\/10.2215\/cjn.04700513","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4034-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4034-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4034-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T19:09:24Z","timestamp":1568920164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4034-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4034"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4034-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"28 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}